-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
Celtic Bank Selects Infinant to Scale Its Embedded Finance Programs
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
-
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled
-
Philadelphia Sexual Assault Lawyer David P. Thiruselvam Explains Who Can Be Named in a Civil Sexual Assault Claim
-
Long Island Capital Alliance to Host Technology Capital Forum
-
BlackBerry and Hazard Management Cayman Islands Renew Critical Alerting System for Emergencies and Public Safety
-
Medical Care Technologies Inc. (OTCID:MDCE) Pauses Dilution Through 2027 After Q3 Profitability Rebound and Infinite Auctions Private Sales Exceed $300,000 in Q4
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Nextech3D.ai Reports Fiscal Q2 2027 Financial Results: AI Event Technology Doubles Revenue
-
Who Is the Best MTF Top Surgeon?
-
Kolter Homes Introduces New Nancy Floorplan at Woodland Preserve in Parrish, Florida
Agronomics Limited Announces Onego Bio Update
Onego Bio Receives FDA "No Questions" Letter on GRAS Status of Bioalbumen(R)
Onego Bio Receives FDA "No Questions" Letter on GRAS Status of Bioalbumen(R)
DOUGLAS, ISLE OF MAN / ACCESS Newswire / September 23, 2025 / Onego Bio Limited ("Onego Bio"), a food ingredient company producing egg protein through precision fermentation, announced today that the U.S. Food and Drug Administration ("FDA") has issued a "no questions" letter regarding the company's conclusion that its flagship product, marketed as Bioalbumen®, is Generally Recognized As Safe ("GRAS") under its conditions of use in a wide range of food and beverage applications.
The FDA's decision, communicated in response to GRAS Notice No. GRN 1249, confirms that Bioalbumen®-a highly functional ovalbumin protein with an amino acid sequence identical to that found in chicken eggs-can be used as a source of dietary protein and, for example, as a foaming, gelling, and binding agent in baked goods, beverages, meat analogs, confections, sauces, and more.
These conclusions from the FDA follows Onego Bio's recent announcement of plans to construct its flagship production facility in Jefferson County, Wisconsin, where the company will scale Bioalbumen® manufacturing to meet sustained high demand, ensuring uninterrupted supply at every level. This milestone increases Onego's confidence in anchoring the facility for their U.S. operations and supports its partnerships with leading food and beverage companies seeking more secure and sustainable commodity ingredients.
Speaking about the announcement, Jim Mellon, Executive Chairman of Agronomics said: "This milestone signals the beginning of what can be a hugely significant industry in the USA. Achieving GRAS status can drive job creation and economic growth at Onego Bio's facility in Wisconsin, as well as answer the need from manufacturers for an ingredient which is not only sustainable, but which can bolster supply chain security too.
The production of clean 'core' ingredients like Bioalbumin®, which have the same benefits and functionality as the ingredients they replace, is becoming increasingly more important as threats to supply chains, such as avian flu and extreme weather, mount. We look forward to continuing our support for clean food technologies such as Onego Bio, as these solutions show what a positive, secure and sustainable food system looks like."
To date, Agronomics has invested a total of £7.1 million in Onego Bio which, subject to audit, is currently carried at £11.2 million. This position represents c.7.5% of Agronomics' last stated Net Asset Value as at 30th of June 2025.
The full announcement is set out below without any material changes:
Onego Bio Receives FDA "No Questions" Letter on GRAS Status of Bioalbumen®
San Diego, USA- September 22, 2025 - Onego Bio, a food ingredient company producing egg protein through precision fermentation, announced today that the U.S. Food and Drug Administration (FDA) has issued a "no questions" letter regarding the company's conclusion that its flagship product, marketed as Bioalbumen®, is Generally Recognized As Safe (GRAS) under its conditions of use in a wide range of food and beverage applications.
The FDA's decision, communicated in response to GRAS Notice No. GRN 1249, confirms that Bioalbumen®-a highly functional ovalbumin protein with an amino acid sequence identical to that found in chicken eggs-can be used as a source of dietary protein and, for example, as a foaming, gelling, and binding agent in baked goods, beverages, meat analogs, confections, sauces, and more.
Produced via precision fermentation with the filamentous fungus Trichoderma reesei, Bioalbumen® delivers high-quality nutrition and matches the functionality of traditional egg protein. It is designed to diversify egg protein sources for food manufacturers, which represents a third of all eggs produced for industrial use, providing a secure supply while reducing price volatility and production disruptions. Additionally, supplementing the industrial egg supply offers a strong defense against the increasing threat of Avian Influenza on food security and public health across the U.S.
"This GRAS "no questions" letter from the FDA is an important milestone for Onego Bio and the culmination of long-term scientific research." said Maija Itkonen, CEO and Co-Founder of Onego Bio. "Bioalbumen® provides the same high-quality nutrition and performance as conventional egg protein. Our U.S. commercial and R&D team continues to sample and provide trial support to an array of food customers ranging from craft bakeries to large scale food manufacturers."
These conclusions from the FDA follows Onego Bio's recent announcement of plans to construct its flagship production facility in Jefferson County, Wisconsin, where the company will scale Bioalbumen® manufacturing to meet sustained high demand, ensuring uninterrupted supply at every level. This milestone increases Onego's confidence in anchoring the facility for their U.S. operations and supports its partnerships with leading food and beverage companies seeking more secure and sustainable commodity ingredients.
"At Onego, integrity and transparency are at the heart of everything we do-our business, our technology, our intellectual property, and our collaboration with customers and partners," added Itkonen. "That's why we pursued the full FDA GRAS review process. Based on that commitment, the FDA's conclusions now confirm our right to commercialize and gives customers full confidence in incorporating Bioalbumen ® as a reliable food solution."
About Onego Bio
Onego Bio is a food ingredient company on a mission to create a more resilient food system through its product Bioalbumen®-the first non-animal egg protein with an amino acid sequence identical to the natural protein. Made through precision fermentation, Bioalbumen® matches the taste, nutrition, and functionality of the main protein from traditional eggs with an environmental impact around 90% smaller. Its unmatched versatility makes it ideal across a wide range of applications, while providing greater cost and supply stability for food manufacturers. Learn more at www.onego.bio.
About Agronomics
Agronomics is a leading London-listed company focusing on investment opportunities within the field of clean food. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to invest in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals.
These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and improve food security for the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.
For further information, please contact:
Agronomics Limited | Beaumont Cornish Limited | Canaccord Genuity Limited | Cavendish Capital Markets Limited | Peterhouse Capital Limited | 33Seconds Limited |
The Company | Nomad | Joint Broker | Joint Broker | Joint Broker | Public Relations |
Jim Mellon Denham Eke | Roland Cornish James Biddle | Andrew Potts Harry Pardoe | Giles Balleny Michael Johnson | Lucy Williams Charles Goodfellow | Jack Ferris Calum Warren-Piper |
+44 (0) 1624 639396 | +44 (0) 207 628 3396 | +44 (0) 207 523 8000 | +44 (0) 207 397 8900 | +44 (0) 207 469 0936 |
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media-only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Agronomics Limited
View the original press release on ACCESS Newswire
E.Flores--AT